8.49
price up icon3.41%   0.28
 
loading
前日終値:
$8.21
開ける:
$8.07
24時間の取引高:
858.32K
Relative Volume:
0.58
時価総額:
$308.35M
収益:
$317.00K
当期純損益:
$-53.47M
株価収益率:
-4.4921
EPS:
-1.89
ネットキャッシュフロー:
$-49.31M
1週間 パフォーマンス:
+54.08%
1か月 パフォーマンス:
+161.23%
6か月 パフォーマンス:
+458.55%
1年 パフォーマンス:
+493.71%
1日の値動き範囲:
Value
$7.97
$8.5899
1週間の範囲:
Value
$5.465
$9.37
52週間の値動き範囲:
Value
$1.10
$9.37

Immuneering Corp Stock (IMRX) Company Profile

Name
名前
Immuneering Corp
Name
セクター
Healthcare (1152)
Name
電話
617-500-8080
Name
住所
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Name
職員
54
Name
Twitter
Name
次回の収益日
2025-08-08
Name
最新のSEC提出書
Name
IMRX's Discussions on Twitter

IMRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
IMRX
Immuneering Corp
8.49 338.38M 317.00K -53.47M -49.31M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
394.53 99.62B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
465.89 61.52B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.00 58.91B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
756.38 46.69B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
324.34 34.54B 3.81B -644.79M -669.77M -6.24

Immuneering Corp Stock (IMRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-13 ダウングレード Morgan Stanley Equal-Weight → Underweight
2024-03-15 ダウングレード Jefferies Buy → Hold
2024-03-15 繰り返されました Needham Buy
2024-03-15 ダウングレード TD Cowen Outperform → Market Perform
2023-12-01 開始されました Needham Buy
2023-06-26 再開されました Oppenheimer Outperform
2023-04-19 アップグレード Mizuho Neutral → Buy
2023-04-19 アップグレード Morgan Stanley Underweight → Equal-Weight
2023-03-30 開始されました Mizuho Neutral
2023-02-03 ダウングレード Morgan Stanley Equal-Weight → Underweight
2022-07-08 開始されました Chardan Capital Markets Buy
2022-04-01 開始されました Oppenheimer Outperform
2022-01-07 開始されました Piper Sandler Overweight
すべてを表示

Immuneering Corp (IMRX) 最新ニュース

pulisher
Sep 12, 2025

What MACD and RSI say about Immuneering CorporationTrade Volume Summary & Advanced Technical Analysis Signals - Newser

Sep 12, 2025
pulisher
Sep 12, 2025

Will Immuneering Corporation rebound enough to break evenJuly 2025 EndofMonth & Reliable Volume Spike Alerts - Newser

Sep 12, 2025
pulisher
Sep 12, 2025

Signal strength of Immuneering Corporation stock in tech scannersWeekly Trend Report & Capital Efficiency Focused Strategies - Newser

Sep 12, 2025
pulisher
Sep 12, 2025

What candlestick patterns are forming on Immuneering CorporationTrade Risk Report & Expert Approved Momentum Trade Ideas - Newser

Sep 12, 2025
pulisher
Sep 12, 2025

Detecting support and resistance levels for Immuneering Corporation2025 Breakouts & Breakdowns & Verified Momentum Stock Alerts - Newser

Sep 12, 2025
pulisher
Sep 11, 2025

Can Immuneering Corporation recover in the next quarter2025 Analyst Calls & Momentum Based Trading Signals - Newser

Sep 11, 2025
pulisher
Sep 11, 2025

Immuneering to announce updated data from Phase 2a trial of Atebimetinib + mGnP - MSN

Sep 11, 2025
pulisher
Sep 11, 2025

Volume spikes in Immuneering Corporation stock – what they mean2025 Trading Volume Trends & Daily Chart Pattern Signal Reports - Newser

Sep 11, 2025
pulisher
Sep 11, 2025

Published on: 2025-09-11 02:15:14 - Newser

Sep 11, 2025
pulisher
Sep 11, 2025

Can trapped investors hope for a rebound in Immuneering Corporation2025 Breakouts & Breakdowns & High Accuracy Swing Trade Signals - Newser

Sep 11, 2025
pulisher
Sep 10, 2025

Oppenheimer reiterates Outperform rating on Immuneering stock ahead of data - Investing.com

Sep 10, 2025
pulisher
Sep 10, 2025

Immuneering Corporation to Host Investor Call and Present Updated Data at Upcoming Scientific Conferences - Quiver Quantitative

Sep 10, 2025
pulisher
Sep 10, 2025

Immuneering to present updated pancreatic cancer survival data - Investing.com

Sep 10, 2025
pulisher
Sep 10, 2025

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 - GlobeNewswire Inc.

Sep 10, 2025
pulisher
Sep 10, 2025

Strategies to average down on Immuneering CorporationWeekly Stock Summary & Smart Money Movement Alerts - Newser

Sep 10, 2025
pulisher
Sep 09, 2025

What earnings revisions data tells us about Immuneering CorporationDay Trade & Free Risk Controlled Daily Trade Plans - Newser

Sep 09, 2025
pulisher
Sep 09, 2025

How to integrate Immuneering Corporation into portfolio analysis toolsJuly 2025 Closing Moves & Safe Entry Point Identification - Newser

Sep 09, 2025
pulisher
Sep 09, 2025

Understanding Immuneering Corporation’s price movementJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - Newser

Sep 09, 2025
pulisher
Sep 08, 2025

Backtesting results for Immuneering Corporation trading strategies2025 Support & Resistance & Low Risk High Reward Trade Ideas - Newser

Sep 08, 2025
pulisher
Sep 08, 2025

Combining price and volume data for Immuneering CorporationWatch List & Verified Momentum Stock Alerts - Newser

Sep 08, 2025
pulisher
Sep 08, 2025

How hedge fund analytics apply to Immuneering Corporation stockEarnings Overview Report & Safe Investment Capital Preservation Plans - Newser

Sep 08, 2025
pulisher
Sep 07, 2025

Has Immuneering Corporation found a price floorMarket Performance Summary & Weekly High Conviction Ideas - Newser

Sep 07, 2025
pulisher
Sep 06, 2025

Can Immuneering Corporation expand into new marketsEarnings Miss & Growth-Oriented Investment Plans - خودرو بانک

Sep 06, 2025
pulisher
Sep 06, 2025

What is the dividend yield of Immuneering CorporationMarket Activity Recap & Weekly Return Optimization Plans - خودرو بانک

Sep 06, 2025
pulisher
Sep 04, 2025

Using Python tools to backtest Immuneering Corporation strategiesJuly 2025 Pullbacks & Weekly Top Gainers Alerts - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Tick level data insight on Immuneering Corporation volatilityJuly 2025 Drop Watch & AI Optimized Trading Strategy Guides - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Custom watchlist performance reports with Immuneering CorporationTrade Risk Summary & Free Growth Oriented Trading Recommendations - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Aug Reactions: Will Immuneering Corporation stock recover after earningsQuarterly Performance Summary & Technical Confirmation Trade Alerts - خودرو بانک

Sep 04, 2025
pulisher
Sep 03, 2025

Can Immuneering Corporation ride the EV waveJuly 2025 Closing Moves & Free Weekly Watchlist of Top Performers - خودرو بانک

Sep 03, 2025
pulisher
Sep 03, 2025

Immuneering Corporation (IMRX) files for up to 9.18M share offering by selling stockholders - StreetInsider

Sep 03, 2025
pulisher
Sep 03, 2025

Buyback Watch: Can Immuneering Corporation deliver consistent dividends2025 Growth vs Value & Verified Swing Trading Watchlist - خودرو بانک

Sep 03, 2025
pulisher
Sep 03, 2025

Can a trend reversal in Immuneering Corporation lead to recoveryJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - Newser

Sep 03, 2025
pulisher
Sep 02, 2025

Order flow analysis tools used on Immuneering CorporationWeekly Gains Summary & High Conviction Trade Alerts - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Building trade automation scripts for Immuneering CorporationBreakout Watch & Safe Swing Trade Setups - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

What momentum shifts mean for Immuneering CorporationRisk Management & Technical Pattern Alert System - Newser

Sep 02, 2025
pulisher
Sep 01, 2025

Is Immuneering Corporation a cyclical or defensive stockShort Setup & Growth Oriented Trading Recommendations - خودرو بانک

Sep 01, 2025
pulisher
Aug 31, 2025

Does Immuneering Corporation show high probability of reboundShare Buyback & Daily Oversold Bounce Ideas - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Needham & Company LLC Reiterates "Buy" Rating for Immuneering (NASDAQ:IMRX) - MarketBeat

Aug 31, 2025

Immuneering Corp (IMRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$36.36
price down icon 0.93%
$83.10
price down icon 3.56%
$27.82
price down icon 2.76%
$96.74
price down icon 7.26%
$145.93
price up icon 0.10%
biotechnology ONC
$324.34
price down icon 3.38%
大文字化:     |  ボリューム (24 時間):